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Recessive mutations in SEC23B gene cause congenital dyserythropoietic anemia type II 
(CDAII),1 a rare hereditary disorder hallmarked by ineffective erythropoiesis, iron overload, and 
reduced expression of hepatic hormone hepcidin.2,3 Some erythroid regulators have been proposed 
as pathological suppressors of hepcidin expression, such as growth differentiation factor 15 
(GDF15) in thalassemia, CDAI and II,4-6 even if alone it seems not necessary for physiological 
hepcidin suppression.7 The most recently described is the erythroblast-derived hormone 
erythroferrone (ERFE), a member of TNF-α superfamily that specifically inhibits hepcidin 
production. ERFE-encoding FAM132B is an erythropoietin (EPO)-responsive gene in experimental 
models.8 However, the function of ERFE in humans remains to be investigated.  
To evaluate ERFE expression in CDAII patients we enrolled 37 SEC23B-related non-transfusion 
dependent patients (Table S1). Ten new cases from 9 unrelated pedigrees were described (Table 
S2). All patients were young adults (19.1±3.0 years at diagnosis), with high transferrin saturation 
(71.4±5.5%). For case-control study, 29 age and gender matched healthy controls (HC) were also 
included (Table S1). See Methods in Supplemental data available on the BloodWeb. 
We observed a statistically significant overexpression of FAM132B gene either in peripheral blood 
leukocytes (PBL) (Figure 1a) or in reticulocytes (Figure S1a) from CDAII patients compared to 
HC. Indeed, a statistically significant correlation between PBL and reticulocyte FAM132B 
expression from the same patients was observed (Spearman ρ=0.78, p=0.02) (Figure S1b). 
Similarly, a marked up-regulation of Erfe in both erythroblasts and PBL from Hbbth3/+mice 
compared to wild type ones was observed (Figure S1c). Of note, approximately 0.03% of 
erythroblasts (CD71+/CD45- cells) were found in PBLs from CDAII patients (data not shown). 
Consistent with previous studies and with the loss of function of SEC23B mutations,9 we observed a 
reduced SEC23B expression in our patients compared to HC (Figure S2a). Indeed, FAM132B and 
SEC23B gene expression exhibited an inverse correlation (Figure S2b). Interestingly, we did not 
observe in our patients the same trend of expression of FAM132A paralog gene, which shares 69% 
of transcript identity with FAM132B (Figure S2c). This suggests a possible involvement of ERFE-
encoding FAM132B in the pathogenesis of hemosiderosis in CDAII. 
During the preparation of this study, two articles reporting measurement of human ERFE protein 
were published.10,11 Accordingly to gene expression analysis, we found an increased ERFE 
expression in CDAII patients compared to HC (Figure 1b). 
Of note, when we analyzed ERFE expression in β-thalassemia (BT)-intermedia patients, exhibiting 
iron overload likewise for CDAII patients (Table S1), we observed similar results compared to 
CDAII. Conversely, only a slight increase of ERFE expression was observed in patients with mild 
well-compensated anemia, such as hereditary spherocytosis (HS) (Figure 1c). These data suggested 
For personal use only.on October 1, 2016. by guest  www.bloodjournal.orgFrom 
Russo R et al 
that the marked increased ERFE expression observed in both CDAII and BT-intermedia patients is 
mainly due to the ineffective erythropoiesis.  
 
As recently reported the ablation of Erfe in thalassemic mice induces a slight amelioration of 
ineffective erythropoiesis but does not improve the anemia.12 In order to explore the possible 
interplay between the levels of erythroferrone and the degree of anemia in CDAII patients, we 
divided our cohort into two sub-groups: low- and high-FAM132B. Unlike thalassemic Erfe-
haploinsufficient mice, we observed a statistically significant reduction in hemoglobin (Hb) level in 
the high-FAM132B subset compared to the low-FAM132B one. Of note, we focused on non-
transfusion dependent patients, thus the expression level of FAM132B was not biased by 
transfusion regimen; however, ERFE expression did not correlate even with the occasional need of 
transfusions (Table 1). The higher expression of ERFE seems to reflect the increase of iron demand 
for Hb production as well as the expanding abnormal erythropoiesis, characterizing CDAII, as 
attested by the increased levels of sTfR and EPO in high-FAM132B patients. This in turn leads to 
reduced hepcidin and hepcidin/ferritin ratio in high-FAM132B group compared to low-FAM132B 
one, resulting in augmented iron delivery to the erythron. Indeed, an inverse correlation between 
FAM132B expression and hepcidin levels was observed (Spearman r -0.49, p = 0.004). However, 
the iron balance data do not differ significantly between the two CDAII sub-groups, even if a trend 
to increased transferrin saturation was observed in high-FAM132B patients (Table 1). Thus, ERFE 
up-regulation may contribute to the inappropriate suppression of hepcidin, but not to account alone 
for the subsequent hemosiderosis observed in CDAII patients.  
 
A high expression of FAM132B in ex vivo EPO-differentiating human erythroblasts has been 
documented.8 Accordingly, we confirmed a progressive increase of FAM132B expression in healthy 
CD34+ progenitors cells EPO-induced to erythroid differentiation. Particularly, we observed a 
significant increase of FAM132B in the transition from basophilic (9d, 3.93±1.32) to polychromatic 
erythroblasts (11d, 14.30±2.46; p=0.02) (Figure 1d). Of note, the onset of multinuclearity in in vitro 
model of CDAII involves polychromatic and orthochromatic precursors.13 Thus, the accumulation 
of highly expressing-FAM132B polychromatic erythroblasts in CDAII marrow could account for 
the pathological over-expression observed in CDAII patients. Our observation is consistent with the 
demonstration that polychromatic erythroblasts are the main source of Erfe in BT mice. Indeed, 
similarly to CDAII erythropoiesis, BT is characterized by an accumulation of polychromatic 
erythroblasts that do not mature to the orthochromatic stage. Thus, the increased Erfe expression in 
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erythroblasts from HbbTh3/+ mice compared to WT mice is mainly due to the relative abundance of 
polychromatic erythroblasts.12 
CDAII is still lacking of a reliable animal model, because SEC23B deficiency results in different 
phenotypes in humans and mice.14,15 So far the only reliable in vitro model for CDAII is the 
SEC23B-silenced K562 cells.1 We established K562 stable clones silenced for SEC23B gene by 
lentiviral shRNAmir targeting human SEC23B, which ensures a highly efficiency of silencing. 
When we induced to erythroid differentiation K562 stable clones silenced for SEC23B, we 
observed a higher expression of FAM132B at 5 days of erythroid differentiation in K562 SEC23B-
silenced cells compared to not-silenced ones (Figure 1e). Conversely, SEC23B expression was 
lower in both K562 SEC23B-stably silenced cell lines compared to K562 sh-CTR cells at 2 and 5 
days of differentiation (Figure S2d). Thus, we confirmed the ex vivo data about inverse correlation 
between FAM132B and SEC23B expression observed in our patients. 
Literature data lacks of information about human ERFE protein. In order to validate our data at 
protein level, we firstly evaluated the good performance of the commercial anti-FAM132B antibody 
we used (Figure S3a-c). We also provided the first demonstration that ERFE protein is N-
glycosylated; indeed, the higher band obtained by WB determination is the glycosylated isoform of 
the same protein, as demonstrated by the digestion pattern after PGNase treatment (Figure S3d). 
Accordingly to gene expression data, we observed an increased level of secreted ERFE in the 
extracellular medium of K562 SEC23B-silenced cells compared to not-silenced ones at 5 days of 
erythroid differentiation, whereas ERFE intracellular level was lower (Figure 1f).  
Although the mechanisms of hemin-induced differentiation are quite different from EPO-induced 
ones, we can hypothesize that ERFE over-expression is related to the maturative arrest and the 
subsequent increased number of erythroid precursors. 
 
This study provides the first analysis on ERFE expression in human model of dyserythropoietic 
anemia with ineffective erythropoiesis, such as CDAII. Our ex vivo and in vitro data indicate that 
ERFE over-expression in CDAII patients might be most likely related to both physiological and 
pathological mechanisms leading to hepcidin suppression in condition of dyserythropoiesis. Indeed, 
we clearly demonstrated that in two different genetic conditions sharing common clinical findings 
and similar pathogenesis, such as CDAII and BT-intermedia, FAM132B over-expression is related 
to the abnormal erythropoiesis. Nevertheless, the absence of a clear correlation between 
erythroferrone levels and CDAII iron balance suggest that ERFE cannot be the only erythroid 
regulator of hepcidin suppression, at least in CDAII patients. 
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FIGURE LEGEND 
 
Figure 1. ERFE expression in CDAII patients and during erythroid differentiation in normal 
and SEC23B-deficient cells 
a) FAM132B mRNA levels (normalized to β-actin) in PBL from 37 CDAII patients and 29 HC. 
Over expression of FAM132B gene in CDAII patients (9.11 ± 0.10) compared to HC (8.32 ± 0.12, p 
< 0.0001) was observed. Data are presented as mean ± SEM. P value by Student t test. b) Human 
protein ERFE evaluation in plasma samples from 29 CDAII patients and 12 HC. Data are presented 
as mean ± SEM. P value by Student t test. c) FAM132B mRNA levels (normalized to β-actin) in 
PBL from 37 CDAII, 21 BT-intermedia, 13 HS patients and 29 HC. Data are presented as mean ± 
SEM. **p<0.0001; *p<0.05 vs HC group (Student t test). d) FAM132B mRNA levels (normalized 
to GADPH) in normal CD34+ cells induced to erythroid differentiation by EPO at 7, 9, 11, and 13 
days. Data are presented as mean ± SEM of 3 experiments. P value by ANOVA test. e) FAM132B 
mRNA levels (normalized to GADPH) in stable clones of K562 silenced for SEC23B at 2 and 5 
days of erythroid differentiation by hemin. Data are presented as mean ± SEM of 3 experiments. 
*p<0.05 (Student t test). f) Immunoblot of ERFE protein in total cell lysate and medium samples 
from SEC23B-silenced K562 cells induced to erythroid differentiation at 2 and 5 days; GAPDH 
was loading control for total cell lysate, while medium samples was normalized by Ponceau red 
staining of the blots. Densitometric analysis of the blot showed on the left (5 days): ERFE protein 
levels of both SEC23B-silenced K562 clones were normalized on sh-CTR K562 clone. O.D., 
optical density. 
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Table 1. FAM132B expression and clinical correlations in CDAII patients 
  
Low FAM132B 
(n = 20) 
High FAM132B 
(n = 17) P
‡
 
Age (years) 25.3 ± 4.9 (16.0; 19) 12.1 ± 2.5 (10.0; 17) 0.03 
Onset symptoms (years) 7.5 ± 2.5 (5.0; 16) 3.2 ± 1.3 (1.3; 16) 0.14 
Gender (Female/Male) 9 (45.0)/11 (55.0) 9 (52.9)/8 (47.1) 0.63 
Complete blood count 
RBC (106/µL) 3.6 ± 0.2 (3.5; 20) 3.2 ± 0.1 (3.3; 17) 0.05 
Hb (g/dL) 10.7 ± 0.5 (10.4; 20) 9.2 ± 0.4 (9.5; 17) 0.02 
Ht (%) 31.7 ± 1.4 (30.6; 20) 27.5 ± 1.2 (28.0; 17) 0.03 
MCV (fL) 89.7 ± 1.8 (90.2; 20) 86.0 ± 2.2 (84.7; 17) 0.20 
MCH (pg) 30.6 ± 0.7 (31.0; 18) 28.9 ± 0.9 (27.9; 17) 0.12 
MCHC (g/dL) 33.8 ± 0.4 (33.5; 19) 33.3 ± 0.3 (33.1; 16) 0.32 
RDW (%) 19.9 ± 2.5 (18.9; 12) 21.8 ± 1.2 (22.0; 15) 0.48 
PLT (103/µL) 373.0 ± 41.1 (290.0; 17) 459.2 ± 69.2 (390.0; 17) 0.30 
Retics abs count (103/µL) 67.4 ± 9.2 (59.2; 20) 87.3 ± 17.5 (79.7; 16) 0.30 
Retics (%) 2.0 ± 0.3 (1.5; 20) 2.7 ± 0.6 (2.2; 16) 0.25 
Reticulocyte Index 1.3 ± 0.2 (1.2; 20) 1.7 ± 0.3 (1.5; 16) 0.38 
Iron balance 
Hepcidin/ferritin 0.04 ± 0.01 (0.02; 16) 0.01 ± 0.003 (0.006; 16) 0.01 
Hepcidin (nM) 5.8 ± 1.9 (2.7; 17) 1.0 ± 0.3 (0.6; 16) 0.02 
Ferritin (ng/mL) 372.1 ± 107.7 (200.0; 19) 168.5 ± 36.0 (99.8; 17) 0.10 
Ferritin level/dosage age§ 32.9 ± 17.2 (14.9; 18) 26.1 ± 8.6 (12.7; 17) 0.73 
Transferrin saturation (%) 67.7 ± 6.8 (62.5; 19) 81.8 ± 7.8 (86.0; 8) 0.23 
Serum iron (µg/dL) 157.8 ± 13.6 (159.5; 18) 162.7 ± 20.4 (172.0; 13) 0.84 
sTfR (mg/L) 3.7 ± 0.4 (3.7; 12) 5.1 ± 0.5 (5.7; 8) 0.04 
Laboratory data and transfusion regimen 
EPO (mIU/mL) 82.5 ± 19.1 (61.9; 14) 154.3 ± 14.5 (170.1; 13) 0.01 
GDF15 (pg/mL) 814.9 ± 251.1 (503.5; 13) 781.9 ± 140.6 (804.0; 9) 0.92 
Total bilirubin (mg/dL) 3.7 ± 0.8 (2.5; 19) 2.3 ± 0.3 (2.1; 16) 0.15 
Unconjugated bilirubin (mg/dL) 3.1 ± 0.8 (2.2; 17) 1.9 ± 0.3 (1.5; 12) 0.22 
Transfusion need (Yes/No) 7 (46.7)/8 (53.3) 10 (58.8)/7 (41.2) 0.49 
Data are not available for all patients. For quantitative variables data are presented as average ± SEM (median; n). For 
qualitative variables data are presented as n (%)/n (%) 
‡
 Student t test for quantitative unpaired data; chi square test for categorical data 
§ Normalization of ferritin by means of “Ferritin level/dosage age ratio”16 
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